Melinda L. Telli, MD, on HER2-Positive Breast Cancer: NCCN Guidelines Update
NCCN 2021 Virtual Annual Conference
Melinda L. Telli, MD, of Stanford Cancer Institute, discusses highlights of the new NCCN Clinical Practice Guidelines in Oncology®, including nonanthracycline, taxane-based regimens as preferred treatments for patients with HER2-positive breast cancer; newly approved combination therapies such as tucatinib plus capecitabine plus trastuzumab, margetuximab plus chemotherapy, and neratinib plus capecitabine; and recommendations for third line and beyond.
The ASCO Post Staff
William J. Gradishar, MD, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the latest recommendations from the National Comprehensive Cancer Network for treating patients with triple-negative breast cancer; data on early-stage and advanced disease; and the role of checkpoint inhibitors, antibody-drug conjugates, and PARP inhibitors.
The ASCO Post Staff
Gabrielle A. Zecha, PA-C, MHA, of Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, and Aaron Begue, MS, RN, NP-C, OCN, of Memorial Sloan Kettering Cancer Center, discuss how advanced practice providers are recruited and trained, ways to retain these valuable health-care professionals in the face of burnout, metrics to measure their productivity, and their future role in cancer care.
The ASCO Post Staff
Lori J. Wirth, MD, of Massachusetts General Hospital Cancer Center, discusses the common molecular alterations across thyroid cancer subtypes; targeted treatments for BRAF V600E–mutant, NTRK–fusion positive, and RET–altered disease; and optimal therapies for patients with multiple types of thyroid cancer.
The ASCO Post Staff
Crystal S. Denlinger, MD, of Fox Chase Cancer Center, and Mary F. Mulcahy, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discuss biomarkers for determining treatment; immune checkpoint inhibitors; when to employ such treatments as platinum/fluoropyrimidine and fam-trastuzumab deruxtecan-nxki; and other second- or later-line therapies such as paclitaxel, ramucirumab, irinotecan-based regimens, and trifluridine/tipiracil.
The ASCO Post Staff
Alexander E. Perl, MD, of the Abramson Cancer Center at the University of Pennsylvania, discusses the major changes in 2021 to the NCCN Clinical Practice Guidelines in Oncology for managing acute myeloid leukemia, including venetoclax plus azacitidine, a new standard of care in patients ineligible for intensive induction; oral azacitidine maintenance in fit patients unable to complete intensive consolidation chemotherapy or proceed to transplant; and an increased focus on minimal residual disease status post-induction.
